Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
25 authors.
Javier Villacieros-ÁlvarezNeurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain.ORCID 0000-0002-5443-1434
Maria SepulvedaNeuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Spain.ORCID 0000-0002-3078-645X
Adrián Valls-CarbóFundación INCE (Iniciativa para las Neurociencias), Madrid, Spain.ORCID 0000-0002-4831-1276
Nicolas FissoloNeurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain.ORCID 0000-0002-7701-9346
Alessandro DinotoNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy.ORCID 0000-0002-3249-4792
Victoria FernándezNeurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain.ORCID 0000-0002-4809-8196
Andreu VilasecaNeurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain.ORCID 0000-0001-8147-8505
Georgina ArrambideNeurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain.ORCID 0000-0002-2657-5510
Lucia GutierrezNeurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain.ORCID 0000-0001-7312-7254
Mireia CastilloNeurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain.ORCID 0000-0001-8979-3219
Luca BolloNeurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain.ORCID 0000-0002-3673-2030
Carmen EspejoNeurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain.ORCID 0000-0001-9949-5901
Sara LlufriuNeuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Spain.ORCID 0000-0003-4273-9121
Yolanda BlancoNeuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Spain.ORCID 0000-0002-1834-0498
Thais ArmangueNeuroimmunology Program, Neurology Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, University of Barcelona, Spain.ORCID 0000-0001-6192-6171
Gary Álvarez BravoGirona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Girona, Spain.ORCID 0000-0003-0342-0177
Ana Quiroga-VarelaNeurodegeneration and Neuroinflammation Research Group, IDIBGI, Girona, Spain.ORCID 0000-0003-1989-7113
Lluís Ramió TorrentàNeurodegeneration and Neuroinflammation Research Group, IDIBGI, Girona, Spain.ORCID 0000-0002-6999-1004
Alvaro Cobo-CalvoNeurology-Neuroimmunology Department and Multiple Sclerosis Center of Catalonia (Cemcat), Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain.ORCID 0000-0002-2574-0721
Mar TintoreNeurology-Neuroimmunology Department and Multiple Sclerosis Center of Catalonia (Cemcat), Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain.ORCID 0000-0001-9999-5359
Jan D LünemannDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Germany.ORCID 0000-0002-3007-708X
Albert SaizNeuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Spain.ORCID 0000-0002-5793-8791
Sara MariottoNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy.ORCID 0000-0002-7806-3103
Xavier MontalbanNeurology-Neuroimmunology Department and Multiple Sclerosis Center of Catalonia (Cemcat), Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain.ORCID 0000-0002-0098-9918
Manuel ComabellaNeurology-Neuroimmunology Department, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute, Barcelona, Spain; and.ORCID 0000-0002-2373-6657
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
BACKGROUND AND
objectivesTo investigate whether CSF 14-3-3 protein levels discriminate aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) from myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple sclerosis (MS) and the association of CSF 14-3-3 protein levels with clinical features in patients with AQP4-NMOSD.
methodsThis was a multicentric retrospective cohort study of patients with AQP4-NMOSD, MOGAD, and MS, with available CSF samples. 14-3-3 protein levels were quantified using ELISA and compared between the 3 conditions. In patients with AQP4-NMOSD, the association between CSF 14-3-3 protein levels and disability outcomes was explored.
resultsA total of 134 patients were included (AQP4-NMOSD, n = 29; MOGAD, n = 43; MS, n = 62). Patients with AQP4-NMOSD had higher 14-3-3 protein levels (median [interquartile range] 4,441.37 [3,240.05-11526.41] arbitrary units (AU)/mL) compared with those with MS (3,169.86 [2,522.65-3,748.57], DISCUSSION: The study suggests a potential role of CSF 14-3-3 protein levels as a biomarker of neuroaxonal damage in AQP4-NMOSD, because of its ability to correlate with disease severity and predict poor clinical recovery. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in individuals presenting with acute myelitis, CSF 14-3-3 differentiates AQP4-NMOSD from MS or MOGAD with a sensitivity of 0.60 (0.30-0.80) and specificity of 0.95 (0.84-1.00).
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Cerebrospinal 14-3-3 Protein Levels as a Neuroaxonal Biomarker in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder. · full record | OpenQuestion